Zifo Expands CMC Data Automation Partnerships with Top Biopharma Companies

Zifo Technologies announced in a press release that seven of the world's top fifteen biopharma companies have adopted its Chemistry, Manufacturing, and Controls (CMC) services. The initiative aims to reduce execution timelines by half and address delays in moving new therapies from development into manufacturing and clinical trials.

Zifo's approach uses targeted AI models to automate the structuring of unstructured CMC data from multiple sources. The models convert this information into standardized, audit-ready formats suitable for submission to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This automation reduces manual transcription errors and administrative workload for scientific teams.

The company stated that more than 90 percent of its experts have scientific backgrounds, which helps ensure regulatory compliance and data integrity during the CMC phase. Its Practical AI Blueprints are designed to integrate with existing infrastructure, minimizing the need for large-scale system changes while supporting continuous global operations.

Zifo said its goal is to help clients streamline the CMC process so that data can move efficiently from laboratory systems to regulatory documentation, accelerating time to production and clinical testing.